Harbour BioMed stake in US drug developer Spruce shows Chinese firms’ growing clout
Shanghai-based Harbour BioMed’s acquisition of a stake in US-based Spruce Biosciences is the latest example of China’s novel drug developers progressing from one-time licensing...









